As states legalize marijuana, some as long as 10 years ago, many are beginning to realize the public health and safety implications of a variety of new high-potency products as questions about possible links to psychosis arise.
MMJ BioPharma Labs is positioned to perform analytical requirements that the Federal government may impose on the industry, as it was recently awarded a DEA schedule 1 cannabis analytical lab license.
